Inhibition of De Novo NAD+ Synthesis by Oncogenic URI Causes Liver Tumorigenesis through DNA Damage

Cancer Cell

Volumn 26, Issue 6, 2014, Pages 826-839

  Tummala, Krishna S ^a   Gomes, Ana L ^a   Yilmaz, Mahmut ^a   Graña, Osvaldo ^b   Bakiri, Latifa ^a   Ruppen, Isabel ^c   Ximénez Embún, Pilar ^c   Sheshappanavar, Vinayata ^d   Rodriguez Justo, Manuel ^e   Pisano, David G ^b   Wagner, Erwin F ^a   Djouder, Nabil ^a  

^a BBVA University Institute for Economic and Social Analysis University of Alcalá   (Spain)

^b Structural Biology and Biocomputing Programme   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d ROYAL LONDON HOSPITAL   (United Kingdom)

^e UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXYANTHRANILATE 3,4 DIOXYGENASE; AROMATIC HYDROCARBON; ARYLFORMAMIDASE; CASPASE 3; CYCLIN D1; CYTOCHROME P450 1A1; CYTOCHROME P450 2E1; DIETHYLNITROSAMINE; ESTROGEN RECEPTOR; GLYCINE METHYLTRANSFERASE; HISTONE H2AX; KYNURENINASE; KYNURENINE; KYNURENINE 3 MONOOXYGENASE; NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; NICOTINAMIDE RIBOSIDE; ONCOPROTEIN; PROTEIN BAX; PROTEIN MAD2; PROTEIN P53; TRYPTOPHAN; TRYPTOPHAN 2,3 DIOXYGENASE; UNCLASSIFIED DRUG; UNCONVENTIONAL PREFOLDIN RPB5 INTERACTOR; REPRESSOR PROTEIN; SIGNAL PEPTIDE; URI1 PROTEIN, HUMAN; URI1 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DNA DAMAGE; HISTONE PHOSPHORYLATION; LIVER CARCINOGENESIS; LIVER CELL; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; PROTEIN EXPRESSION; ANIMAL; C57BL MOUSE; EXPERIMENTAL LIVER NEOPLASM; GENE EXPRESSION REGULATION; GENETICS; HUMAN; LIVER TUMOR; METABOLISM; MOLECULAR GENETICS; PATHOLOGY; PROTEOMICS;

ANIMALS; CARCINOMA, HEPATOCELLULAR; DIETHYLNITROSAMINE; DNA DAMAGE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEPATOCYTES; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LIVER NEOPLASMS; LIVER NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; NAD; PROTEOMICS; REPRESSOR PROTEINS;

EID: 84919497464     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccell.2014.10.002     Document Type: Article

References (46)

1. Boulon S., Pradet-Balade B., Verheggen C., Molle D., Boireau S., Georgieva M., Azzag K., Robert M.C., Ahmad Y., Neel H., et al. HSP90 and its R2TP/Prefoldin-like cochaperone are involved in the cytoplasmic assembly of RNA polymerase II. Mol. Cell 2010, 39:912-924.
2. Burns R.O., Demoss R.D. Properties of tryptophanase from Escherichia coli. Biochim. Biophys. Acta. 1962, 65:233-244.
3. Carpenter B., Lin Y., Stoll S., Raffai R.L., McCuskey R., Wang R. VEGF is crucial for the hepatic vascular development required for lipoprotein uptake. Development 2005, 132:3293-3303.
4. Chen C.F., Lee W.C., Yang H.I., Chang H.C., Jen C.L., Iloeje U.H., Su J., Hsiao C.K., Wang L.Y., You S.L., et al. Changes in serum levels of HBV DNA and alanine aminotransferase determine risk for hepatocellular carcinoma. Gastroenterology 2011, 141:1240-1248. 1248 e1241-1242.
5. Dapito D.H., Mencin A., Gwak G.Y., Pradere J.P., Jang M.K., Mederacke I., Caviglia J.M., Khiabanian H., Adeyemi A., Bataller R., et al. Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell 2012, 21:504-516.
6. Djouder N., Metzler S.C., Schmidt A., Wirbelauer C., Gstaiger M., Aebersold R., Hess D., Krek W. S6K1-mediated disassembly of mitochondrial URI/PP1gamma complexes activates a negative feedback program that counters S6K1 survival signaling. Mol. Cell 2007, 28:28-40.
7. Durkacz B.W., Omidiji O., Gray D.A., Shall S. (ADP-ribose)n participates in DNA excision repair. Nature 1980, 283:593-596.
8. El-Serag H.B. Hepatocellular carcinoma. N.Engl. J. Med. 2011, 365:1118-1127.
9. Fan Y., Boivin G.P., Knudsen E.S., Nebert D.W., Xia Y., Puga A. The aryl hydrocarbon receptor functions as a tumor suppressor of liver carcinogenesis. Cancer Res. 2010, 70:212-220.
10. Herranz D., Muñoz-Martin M., Cañamero M., Mulero F., Martinez-Pastor B., Fernandez-Capetillo O., Serrano M. Sirt1 improves healthy ageing and protects from metabolic syndrome-associated cancer. Nat. Commun. 2010, 1:3.
11. Hsieh Y.C., Yu H.P., Frink M., Suzuki T., Choudhry M.A., Schwacha M.G., Chaudry I.H. G protein-coupled receptor 30-dependent protein kinase A pathway is critical in nongenomic effects of estrogen in attenuating liver injury after trauma-hemorrhage. Am. J. Pathol. 2007, 170:1210-1218.
12. Ito A., Lai C.H., Zhao X., Saito S., Hamilton M.H., Appella E., Yao T.P. p300/CBP-mediated p53 acetylation is commonly induced by p53-activating agents and inhibited by MDM2. EMBO J. 2001, 20:1331-1340.
13. Kang J.S., Wanibuchi H., Morimura K., Gonzalez F.J., Fukushima S. Role of CYP2E1 in diethylnitrosamine-induced hepatocarcinogenesis invivo. Cancer Res. 2007, 67:11141-11146.
14. Knoblauch R., Garabedian M.J. Role for Hsp90-associated cochaperone p23 in estrogen receptor signal transduction. Mol. Cell. Biol. 1999, 19:3748-3759.
15. Konishi Y., Takahashi S., Nakae D., Uchida K., Tsutsumi M., Shiraiwa K., Denda A. Possible model of liver carcinogenesis using inhibitors of NAD+ ADP ribosyl transferase in rats. Toxicol. Pathol. 1986, 14:483-488.
16. Kudo M. Multistep human hepatocarcinogenesis: correlation of imaging with pathology. J.Gastroenterol. 2009, 44(Suppl 19):112-118.
17. Lee M.H., Yang H.I., Lu S.N., Jen C.L., Yeh S.H., Liu C.J., Chen P.J., You S.L., Wang L.Y., Chen W.J., Chen C.J. Hepatitis C virus seromarkers and subsequent risk of hepatocellular carcinoma: long-term predictors from a community-based cohort study. J.Clin. Oncol. 2010, 28:4587-4593.
18. Liao Y.J., Liu S.P., Lee C.M., Yen C.H., Chuang P.C., Chen C.Y., Tsai T.F., Huang S.F., Lee Y.H., Chen Y.M. Characterization of a glycine N-methyltransferase gene knockout mouse model for hepatocellular carcinoma: Implications of the gender disparity in liver cancer susceptibility. Int. J. Cancer 2009, 124:816-826.
19. Libbrecht L., Craninx M., Nevens F., Desmet V., Roskams T. Predictive value of liver cell dysplasia for development of hepatocellular carcinoma in patients with non-cirrhotic and cirrhotic chronic viral hepatitis. Histopathology 2001, 39:66-73.
20. Luedde T., Kaplowitz N., Schwabe R.F. Cell death and cell deathresponses in liver disease: Mechanisms and clinical relevance. Gastroenterology 2014, 147:765. e4.
21. Luo J., Nikolaev A.Y., Imai S., Chen D., Su F., Shiloh A., Guarente L., Gu W. Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell 2001, 107:137-148.
22. Malhi H., Gores G.J. Cellular and molecular mechanisms of liver injury. Gastroenterology 2008, 134:1641-1654.
23. Menon S., Yecies J.L., Zhang H.H., Howell J.J., Nicholatos J., Harputlugil E., Bronson R.T., Kwiatkowski D.J., Manning B.D. Chronic activation of mTOR complex 1 is sufficient to cause hepatocellular carcinoma in mice. Sci. Signal. 2012, 5:ra24.
24. Michael A.F., Drummond K.N., Doeden D., Anderson J.A., Good R.A. Tryptophan metabolism in man. J.Clin. Invest. 1964, 43:1730-1746.
25. Murga M., Campaner S., Lopez-Contreras A.J., Toledo L.I., Soria R., Montaña M.F., D'Artista L., Schleker T., Guerra C., Garcia E., et al. Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors. Nat. Struct. Mol. Biol. 2011, 18:1331-1335.
26. Naugler W.E., Sakurai T., Kim S., Maeda S., Kim K., Elsharkawy A.M., Karin M. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 2007, 317:121-124.
27. Nunnari G., Pinzone M.R., Cacopardo B. Lack of clinical andhistological progression of chronic hepatitis C in individuals with true persistently normal ALT: the result of a 17-year follow-up. J.Viral Hepat. 2013, 20:e131-e137.
28. Perdew G.H. Association of the Ah receptor with the 90-kDa heat shock protein. J.Biol. Chem. 1988, 263:13802-13805.
29. Pilati C., Letouzé E., Nault J.C., Imbeaud S., Boulai A., Calderaro J., Poussin K., Franconi A., Couchy G., Morcrette G., et al. Genomic profiling of hepatocellular adenomas reveals recurrent FRK-activating mutations and the mechanisms of malignant transformation. Cancer Cell 2014, 25:428-441.
30. Rajamohan S.B., Pillai V.B., Gupta M., Sundaresan N.R., Birukov K.G., Samant S., Hottiger M.O., Gupta M.P. SIRT1 promotes cell survival under stress by deacetylation-dependent deactivation of poly(ADP-ribose) polymerase 1. Mol. Cell. Biol. 2009, 29:4116-4129.
31. Reinhardt H.C., Schumacher B. The p53 network: cellular and systemic DNA damage responses in aging and cancer. Trends Genet. 2012, 28:128-136.
32. Roessler S., Jia H.L., Budhu A., Forgues M., Ye Q.H., Lee J.S., Thorgeirsson S.S., Sun Z., Tang Z.Y., Qin L.X., Wang X.W. Aunique metastasis gene signature enables prediction of tumor relapse inearly-stage hepatocellular carcinoma patients. Cancer Res. 2010, 70:10202-10212.
33. Schuler M., Dierich A., Chambon P., Metzger D. Efficient temporally controlled targeted somatic mutagenesis in hepatocytes of the mouse. Genesis 2004, 39:167-172.
34. Schwabe R.F., Jobin C. The microbiome and cancer. Nature Reviews 2013, 13:800-812.
35. Subramanian A., Tamayo P., Mootha V.K., Mukherjee S., Ebert B.L., Gillette M.A., Paulovich A., Pomeroy S.L., Golub T.R., Lander E.S., Mesirov J.P. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 2005, 102:15545-15550.
36. Surjana D., Halliday G.M., Damian D.L. Role of nicotinamide in DNA damage, mutagenesis, and DNA repair. J.Nucleic Acids 2010, 2010:2010.
37. Teoh N.C., Dan Y.Y., Swisshelm K., Lehman S., Wright J.H., Haque J., Gu Y., Fausto N. Defective DNA strand break repair causes chromosomal instability and accelerates liver carcinogenesis in mice. Hepatology 2008, 47:2078-2088.
38. Theurillat J.P., Metzler S.C., Henzi N., Djouder N., Helbling M., Zimmermann A.K., Jacob F., Soltermann A., Caduff R., Heinzelmann-Schwarz V., et al. URI is an oncogene amplified in ovarian cancer cells and is required for their survival. Cancer Cell 2011, 19:317-332.
39. Trinidad A.G., Muller P.A., Cuellar J., Klejnot M., Nobis M., Valpuesta J.M., Vousden K.H. Interaction of p53 with the CCT complex promotes protein folding and wild-type p53 activity. Mol. Cell 2013, 50:805-817.
40. Verma M., Shulga N., Pastorino J.G. Sirtuin-3 modulates Bak- and Bax-dependent apoptosis. J.Cell Sci. 2013, 126:274-288.
41. Vesselinovitch S.D., Mihailovich N. Kinetics of diethylnitrosamine hepatocarcinogenesis in the infant mouse. Cancer Res. 1983, 43:4253-4259.
42. Vizcaino J.A., Cote R.G., Csordas A., Dianes J.A., Fabregat A., Foster J.M., Griss J., Alpi E., Birim M., Contell J., et al. The PRoteomics IDEntifications (PRIDE) database and associated tools: status in 2013. Nucleic Acids Res. 2013, 41:D1063-D1069.
43. Walisser J.A., Glover E., Pande K., Liss A.L., Bradfield C.A. Aryl hydrocarbon receptor-dependent liver development and hepatotoxicity are mediated by different cell types. Proc. Natl. Acad. Sci. USA 2005, 102:17858-17863.
44. Tumours of the liver andintrahepatic bile ducts. Pathology andGenetics of Tumors of the Digestive System 2008, WHO, IARC Press. http://www.iarc.fr/en/publications/pdfs-online/pat-gen/bb2/BB2.pdf, S.R. Hamilton, L.A. Aaltonen (Eds.).
45. Wurmbach E., Chen Y.B., Khitrov G., Zhang W., Roayaie S., Schwartz M., Fiel I., Thung S., Mazzaferro V., Bruix J., et al. Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. Hepatology 2007, 45:938-947.
46. Yoshimoto S., Loo T.M., Atarashi K., Kanda H., Sato S., Oyadomari S., Iwakura Y., Oshima K., Morita H., Hattori M., et al. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature 2013, 499:97-101.